R

TransCode Therapeutics
D

RNAZ

2.88000
USD
-0.47
(-14.03%)
Post Trading·3.04000USD+0.16000(+5.56%)
حجم التداول
0
الربح لكل سهم
-9
العائد الربحي
-
P/E
-0
حجم السوق
3,048,425
المقالات
المزيد

العنوان: TransCode Therapeutics Inc

القطاع: الرعاية الصحية
الصناعة: Biotechnology
TransCode Therapeutics Inc is a clinical-stage biotechnology company engaged in the development of RNA-based therapeutics and immuno-oncology treatments for cancer. The company's lead candidate, TTX-MC138, targets microRNA-10b and has completed a Phase 1a clinical trial, while it is also advancing additional product candidates, including a cancer vaccine and an oncolytic immunotherapy platform.